checkAd
    Aktie
    ISIN: CNE100003PG4 WKN: A2PV00 SYM: 17Q1 Land China
    Zur Watchlist hinzufügen Zum Portfolio hinzufügen
    1,0500
     
    EUR
    +2,94 %
    +0,0300 EUR
    Letzter Kurs 17.07.24 Tradegate
    Geldkurs
    20:25:14
    1,0200
     
    EUR
    4.948 STK
    Briefkurs
    20:25:14
    1,0700
     
    EUR
    4.647 STK

    Pharmaron Beijing Ltd. Registered (H) Aktie kaufen

    Pharmaron Beijing Ltd. Registered (H) Bilanz & GuV

    GuV in Mio EUR

    20192020202120222023
    Umsatz3.757,165.133,607.443,7710.266,2911.538,00
    Bruttoergebnis vom Umsatz1.334,381.923,522.678,923.768,404.124,48
    EBITDA1.024,631.629,712.597,282.614,392.917,32
    EBIT631,491.323,831.914,341.689,891.990,14
    Ergebnis vor Steuer632,551.319,371.911,001.666,391.837,89
    Ergebnis nach Steuern547,191.172,381.661,031.374,601.601,10

    Bilanz in Mio EUR

    20192020202120222023
    Aktiva9.935,0411.908,7918.389,1220.492,5626.476,71
    Umlaufvermögen5.944,455.540,388.643,506.536,0110.874,41
    Summe Anlagevermögen3.990,596.368,419.745,6213.956,5515.602,30
    Passiva9.935,0411.908,7918.389,1220.492,5626.476,71
    Summe kurzfristige Verbindlichkeiten1.269,681.981,792.982,003.912,433.654,48
    Summe langfristige Verbindlichkeiten827,34993,265.111,825.740,269.584,19
    Summe Fremdkapital2.097,022.975,058.093,829.652,6913.238,67
    Bilanzielles Eigenkapital7.767,068.870,3210.129,2410.548,6212.556,80

    Cashflow in EUR

    20192020202120222023
    Cashflow938,59 Mio.1,65 Mrd.2,06 Mrd.2,14 Mrd.2,75 Mrd.

    Dividende

    20192020202120222023
    Dividendenausschüttung in Mio.143,19135,40284,72404,76444,79
    Kennzahlen und Daten von

    Pharmaron Beijing Ltd. Registered (H) Unternehmensprofil

    Pharmaron Beijing Ltd. Registered (H) Insidertrades 2024

    Kennzahlen in EUR

    201920202021202220232024e
    Dividendenrendite--0,19 %0,80 %1,87 %2,56 %
    Kurs-Gewinn-Verhältnis (KGV)-74,4745,0641,5515,967,15
    Kurs-Cash-Flow-Verhältnis (KCV)-53,0436,4626,639,33
    Kurs-Buchwert-Verhältnis (KBV)-9,867,395,412,04
    Kurs-Umsatz-Verhältnis (KUV)-17,0310,065,562,22
    Umsatz je Aktie3,824,336,278,676,46
    Cashflow je Aktie0,951,391,731,811,54
    Umsatzrentabilität14,56 %22,84 %22,31 %13,39 %13,88 %
    Eigenkapitalrendite7,05 %13,22 %16,40 %13,03 %12,75 %
    Anlageintensität40,00 %53,00 %53,00 %68,00 %59,00 %
    Arbeitsintensität60,00 %47,00 %47,00 %32,00 %41,00 %
    Gesamtrendite5,51 %9,84 %9,03 %6,71 %6,05 %
    Eigenkapitalquote78,18 %74,49 %55,08 %51,48 %47,43 %
    Fremdkapitalquote21,11 %24,98 %44,01 %47,10 %50,00 %
    Verschuldungsgrad27,00 %33,54 %79,91 %91,51 %105,43 %
    ‎Liquidität 1. Grades350,00 %148,00 %118,00 %37,00 %-
    ‎Liquidität 2. Grades431,00 %212,00 %171,00 %97,00 %-
    ‎Liquidität 3. Grades444,00 %226,00 %194,00 %123,00 %-
    Working Capital in Mio.4.674,773.558,595.661,512.623,577.219,94
    Deckungsgrad A194,63 %139,29 %103,94 %75,58 %80,48 %
    Deckungsgrad B208,26 %145,49 %149,32 %107,50 %133,03 %
    Deckungsgrad C200,36 %139,32 %139,58 %100,03 %124,92 %

    Aktieninformationen in EUR

    201920202021202220232024e
    Aktien im Umlauf in Mio.984,611.185,331.186,501.184,191.786,731.786,73

    Mitarbeiter

    2024e
    Anzahl Mitarbeiter20.295


    Aktionärsstruktur

    Profil

    Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, rest of Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Preparation Process Development, and Production Services; Clinical Research Services; Macromolecule and Cell, and Gene Therapy Services; and Others. The company offers laboratory chemical services, including medicinal chemistry, synthetic chemistry, analytical and purification chemistry, and computer-aided drug design; bioscience services, such as in vitro and in vivo drug metabolism and pharmacokinetics, in vitro biology and in vivo pharmacology, drug safety evaluation, and US laboratory services; and process development and production, material science/preparation, preparation development and production, and analytical development services. It also provides radiolabeling science and early clinical trial services; clinical trial and clinical research site management services; and macromolecular drug discovery and development, and production services (CDMO), as well as cell and gene therapy laboratory, and gene therapy CDMO services. In addition, the company provides safety assessment, and chemistry, manufacturing, and controls services. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the Peoples Republic of China.

    Kennzahlen und Daten von